325 Mesh Silica: Particle Size, Specifications and Common Applications

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Alumina Powder vs Silica Powder: Properties, Uses and How to Choose
  • Keywords: matting agent supplier
  • Published: 2026-11-20 07:25:41
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
24. Zhang Y., Wang J., Bai X., Jiang T., Zhang Q., Wang S. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol. Pharm. 2012;9:505-513. doi: 10.1021/mp200287c. [ DOI ] [ PubMed ] [ Google Scholar ]

Silica SDS: Key Hazards, Handling and Storage Information Explained

What Is the Boiling Point of Silica (SiO₂)? Thermal Properties Explained
Quartz Sand Price: 2026 Price Ranges by Purity and Mesh Size
Thermal Conductive Filler: Silica vs Alumina vs Boron Nitride Compared
29. Porrang S., Davaran S., Rahemi N., Allahyari S., Mostafavi E. How Advancing are Mesoporous Silica Nanoparticles? A Comprehensive Review of the Literature. Int. J. Nanomed. 2022;17:1803-1827. doi: 10.2147/IJN.S353349. [ DOI ] [ PMC free piece ] [ PubMed ] [ Google Scholar ]
Matting Agent Supplier: How to Choose the Right Silica Matting Agent Partner
Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].

Silica Supplier Middle East: Sourcing Options, Logistics and Key Markets

What is silica (SiO₂)?

transparent silica filler One of the biggest challenges of tableting greatly potent APIs (antibiotics, hormones, cytostatic molecules) is to attain content uniformity [ 95, 96 ]. Since these molecules are used in small doses, it is demanding to attain a homogeneous powder mixture during mixing and to make sure this homogeneity until the end of tableting. Also, it is a hurdle to develop a reproducible method that ensures content uniformity for each production batch, since the specified dose must be made sure between batches, not just within one batch [ 95, 96 ]. A reliable alternative method is to use mesoporous silica as a carrier system rather than simple powder mixing, thus preventing the segregation and aggregation of the low-dose API during mixing and compression. In this case, the preloaded mesoporous carrier and the necessary excipients are mixed, and then the powder mixture can be compressed directly or after granulation. The drug loading can be controlled by the concentration of the drug solution used to fill the carrier systems, which affects the amount of the drug content in the concluding medicine [ 95, 96 ]. Based on this, nearly unlimitedly low doses can be formulated into tablets, even in a concentration of 0.01%, just by properly preparing the solution [ 96 ]. The technique is well-controllable and dependable, since each tablet has the same drug content and the desired content uniformity. Furthermore, the method can be used in both batch-based and continuous production [ 96 ]. This may be a promising finding because there is evidence that it is challenging to move from batch-based to continuous manufacturing while maintaining the desired drug content and content uniformity [ 94 ]. But it should be noted that in this study, no nanocarrier system was used [ 94 ], so utilizing MSN formulations could make an enormous improvement in developing continuous tablet manufacturing [ 96 ]. A study shown that MSN carriers can also be used in orodispersible films to enhance the dissolution of poorly water-soluble drugs [ 100 ]. Based on in vitro drug release studies, more than 90% of prednisolone was released within 2 min when the loaded MSN was incorporated into the formulation. This means a much faster, immediate release in comparison with formulations containing the free form of the drug. In addition, precise dosing can be accomplished utilizing nanocarriers for personalized medication; furthermore, enabling the production of low-dose preparations without content uniformity problems [ 100 ].

What is the difference between fumed silica and precipitated silica?

what is silica MSNs are also appropriate for pulmonary drug delivery. Inhalation is an attractive route of administration since the application is non-invasive and patient-friendly [ 18 ]. However, the rapid mucociliary clearance and the mucus hurdle complicate the intake of the API and are obstacles to be overcome [ 18, 25 ]. The mesoporous drug delivery systems may be really helpful in the treatment of lung diseases, as they can passively accumulate in the alveoli [ 25, 56, 72 ]. The passive accumulation is due to their small size, while the sizable surface area, high vascularity, and vascular permeability of the lungs enhance the process [ 56 ]. Furthermore, targeted treatment of tumors or inflamed cells can also be implemented with the functionalization of their surface [ 56, 72 ]. MSNs are typically delivered to the lungs in powder form with dry powder inhalers or suspended in liquid droplets with a nebulizer [ 56 ].

What drives silica raw material prices?

fumed silica brands

Cite this article: Silica Raw Materials News. "Silica Free Flow Agent: Typical Dosage, Benefits and Best Grades ." Published 2026-11-20 07:25:41. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.